Objectives: Plasma concentrations are frequently used for therapeutic drug monitoring of antiretroviral drugs. Dried blood spot sampling offers a patient-friendly and easy alternative to plasma sampling. However, dried blood spot concentrations are not necessarily equal to plasma concentrations and therefore the objective of this work was to establish the relationship between nevirapine and efavirenz dried blood spot and plasma concentrations to facilitate clinical implementation of dried blood spot sampling.
Introduction
Approximately 33.3 million people are currently living with HIV. 1 Since the introduction of combined antiretroviral treatment (cART) the morbidity and mortality of HIV-infected individuals has decreased dramatically. Guidelines from the European AIDS Clinical Society and the Department of Health and Human Services in the USA recommend HIV treatment with two nucleoside reverse transcriptase inhibitors combined with a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor (NNRTI) or raltegravir. 2, 3 Unfortunately, the emergence of resistance and the occurrence of adverse events often limit the therapeutic success of antiretroviral drugs.
Plasma concentrations of the NNRTIs nevirapine and efavirenz have been related to virological outcome and toxicity in HIV-infected patients. 4, 5 Therefore, therapeutic drug monitoring (TDM) of nevirapine and efavirenz is recommended in special populations (e.g. children and pregnant women) and for selected indications (such as certain drug -drug interactions) to minimize toxicity and maximize virological outcome. 6 Currently, TDM is performed by measurement of plasma concentrations. However, venous sampling has several drawbacks, including the requirements for trained personnel and specialized equipment for sample processing. Additionally, measurement of trough levels is often advised for TDM, which is difficult to perform in an outpatient clinic with the current dosing regimens (once or twice daily) of antiretroviral agents.
Dried blood spots (DBS) offer a patient-friendly and easy alternative. DBS can be collected by patients with a simple finger prick, after which blood is collected on filter paper cards. This technique has previously been used for TDM of several other drugs. 7 The cards can be stored at room temperature after air drying. However, before the use of DBS can be implemented in clinical practice, a comparison between DBS and plasma concentrations is required since DBS concentrations are not necessarily equal to plasma concentrations. For instance, the fraction of analyte bound to plasma proteins (f bpp ) and the haematocrit may influence DBS concentrations. 8, 9 Therefore, the objective of this work was to compare nevirapine and efavirenz concentrations between DBS and plasma using two previously validated HPLC-tandem mass spectrometry (MS/MS) methods developed for these matrices.
10,11

Methods
Patients
For this study, 40 HIV-infected patients on an efavirenz-based regimen and 40 HIV-infected patients on a nevirapine-based regimen were recruited from the outpatient clinic of the Slotervaart Hospital, Amsterdam, The Netherlands. The number of patients was based upon the guidelines for method comparison and bias estimation using patient samples from the CLSI. 12 Besides the regimen, no further inclusion criteria were used. Patients were recruited between December 2010 and May 2011. Patient characteristics were obtained from patient files. Additionally, patients were asked for their timing of last efavirenz or nevirapine intake. This study was approved by the local ethics committee and informed consent was provided by each participant before blood sampling.
Sampling
DBS samples were obtained within 5 min after venepuncture, for the collection of EDTA whole blood, from each patient during regular visits to the outpatient clinic. Plasma samples were obtained from the EDTA whole blood samples after centrifugation and were stored at 2208C until further analysis. After sterile cleaning of the skin, a lancet puncture was performed for DBS sampling. The first drop of blood was discarded and subsequent blood drops were collected on filter paper cards (Protein Saver 903 card, Whatman Nederland B.V., Den Bosch, The Netherlands). After overnight air drying, DBS samples were stored at room temperature in a foil bag with a desiccant package according to the manufacturer's instructions pending further analysis.
Bioanalysis
Bioanalysis of nevirapine and efavirenz concentrations was performed using two previously validated HPLC-MS/MS assays for the determination of NNRTIs and protease inhibitors in plasma and DBS. 10, 11 In short, sample pretreatment of plasma consisted of protein precipitation with a mixture of methanol and acetonitrile (50: 50, v/v) that contained internal standards. For DBS, the analytes were extracted from a 0.6 cm diameter punched-out disc, corresponding to 15 mL of whole blood, using a mixture of methanol, acetonitrile and 0.2 M zinc sulphate in water (1 :1 : 2, v/v/v) with internal standards. Chromatographic separation was performed on a reversed-phase C18 column with a stepwise gradient using a mobile phase consisting of methanol with 10 mM ammonium acetate buffer pH 5 (35: 65, v/v) and methanol. An API 3000 triple quadrupole mass spectrometer operating in the positive ionization mode was used for quantification of nevirapine and efavirenz (mass transitions of 267/226 and 316/244 m/z, respectively). For the determination of nevirapine and efavirenz in plasma, calibration and quality control standards were prepared in plasma. The assay was validated over a range of 0.1-20 mg/L with accuracy ranging from 89.8% to 99.9% and imprecision was ,8.1%. The recovery rate was high and reproducible (82.5%-99.6%, SD ≤4.7%, and 85.3%-97.2%, SD ≤6.2%, for nevirapine and efavirenz, respectively) and ion suppression was ,10% for both compounds. For the DBS method the calibration and quality control samples were freshly prepared in DBS. The validated range for the DBS method was similar to that for the plasma method, with accuracy and imprecision ranging from 98.3% to 104.2% and from 3.4% to 12.3%, respectively. The recovery rate was high and reproducible (100.1%-103.6%, SD ≤15.3% and 101.8%-104.4%, SD ≤17.5% for nevirapine and efavirenz, respectively) and ion suppression was found to be negligible. Nevirapine and efavirenz were stable for at least 7 months in DBS when stored at room temperature in a foil bag with a desiccant package (our own unpublished stability data).
Statistics
Patient characteristics were described using standard descriptive techniques. DBS and plasma concentrations were compared using linear regression. Additionally, theoretical plasma concentrations were calculated from DBS concentrations using the following formula: [DBS [analyte] /(12 haematocrit)]×f bpp ¼plasma [analyte] . The f bpp was 0.6 and 0.995 for nevirapine and efavirenz, respectively. 13 To make this method easy to use in clinical practice, theoretical plasma concentrations were calculated from DBS concentrations using a mean haematocrit value for males (0.45 L/L) since our outpatient HIV population consists mainly of males.
14 Both theoretical plasma concentrations were compared with measured plasma concentrations using linear regression and the Bland-Altman approach. 15 The paired t-test was used to assess differences between the theoretical plasma concentrations using patientspecific haematocrit and mean haematocrit values for males. Additionally, measured efavirenz plasma concentrations as well as the theoretical efavirenz plasma concentrations using either patient-specific haematocrit or mean haematocrit of males were categorized according to international consensus on TDM of efavirenz to show the clinical applicability of DBS sampling. 2 Plasma levels ,1.0 mg/L increase the chance of virological failure, while central nervous side effects are increased with plasma levels .4.0 mg/L. Plasma levels between 1.0 and 4.0 mg/L are considered adequate. Paired results were compared for discrepancies in categorization that may have resulted in a different clinical intervention. No categorization was performed for nevirapine since no therapeutic range has been established for the once-daily 400 mg dose.
Results
Patients
The characteristics of the 80 included patients are summarized in Table 1 . Most patients were male (94%) and in a good immunological and virological state. None of the included patients had a viral load .50 copies/mL. The average CD4 cell count was 621 cells/mm 3 (range 116 -1560 cells/mm
DBS versus plasma concentrations
The relationships between nevirapine and efavirenz concentrations in DBS and plasma are plotted in Figure 1 and showed good correlations (r 2 ¼ 0.867 and 0.972 for nevirapine and efavirenz, respectively). The DBS concentrations of efavirenz were, however, 39.8% (SD 7.1%) lower than the corresponding plasma concentrations. For nevirapine, the DBS and corresponding plasma concentrations were almost identical. The linear relationship between theoretical nevirapine and efavirenz plasma concentrations {using the formula [DBS [analyte] /(12haematocrit)]× f bpp ¼ plasma [analyte] with patient-specific haematocrit} and measured plasma concentrations are plotted in Figure 2 (a) and 2(b), respectively. The relationship almost equalled the line of true identity. When using mean haematocrit for males to calculate the theoretical plasma concentration, similar plots were seen (r 2 ¼ 0.867 and 0.972 for nevirapine and efavirenz, respectively). Figure 3 shows the Bland -Altman plots of both compounds using patientspecific and mean haematocrit for males. The mean difference in nevirapine and efavirenz concentrations between the theoretical plasma concentration using patient-specific haematocrit and measured plasma concentration was 0.29 mg/L (SD 1.35 mg/L) and 0.08 mg/L (SD 0.31 mg/L), respectively, whereas this difference was 0.43 mg/L (SD 1.21 mg/L) and 0.17 mg/L (SD 0.29 mg/L) when using the mean haematocrit for males. The mean differences between these two methods were significantly different for both nevirapine and efavirenz (P ¼ 0.007 and 0.009, respectively). Table 2 shows the discrepancies in categorization for efavirenz. In 10% (n¼ 4) of the cases, theoretical plasma concentrations were categorized differently from corresponding plasma concentrations.
Discussion
In this study we demonstrated that DBS concentrations of nevirapine and efavirenz showed good agreement with plasma concentrations after correction for haematocrit and compoundspecific plasma protein binding.
Previously, four studies evaluated the correlation between antiretroviral drug concentrations in DBS and plasma. Van Schooneveld et al. 16 demonstrated in 48 individual patient samples that atazanavir DBS concentrations correlated well with plasma concentrations (r 2 ¼0.988), although DBS concentrations were slightly lower (210.8%) than plasma concentrations. Koal et al. 17 evaluated 70 patient samples (lopinavir, atazanavir, ritonavir, saquinavir and efavirenz) for DBS and plasma concentrations. A summary correlation curve showed a good correlation (r 2 ¼ 0.9772) for all compounds; however, DBS concentrations again were slightly lower (215%) than the corresponding plasma concentrations. Meesters et al. 18 showed the correlation between lopinavir and ritonavir in 19 DBS and plasma samples from children (r 2 ¼ 0.8487 and 0.7679, respectively). These DBS samples were, however, obtained from whole blood samples (not from a finger prick) and no bias estimation Nevirapine and efavirenz in dried blood spots 1213 JAC was performed. Our group previously showed that DBS concentrations of etravirine, darunavir, raltegravir and ritonavir were proportional to plasma concentrations obtained from cell preparation tubes. 19 Thus, all previous authors reported that DBS and plasma concentrations correlated well, although the concentrations were not identical. This study showed similar results; nevirapine and efavirenz DBS concentrations correlated well with plasma concentrations, although DBS concentrations of efavirenz were 39.8% (SD 7.1%) lower than plasma concentrations. None of the previous authors investigated the mechanism behind the nonsimilarity between DBS and plasma concentrations. We, however, now show that the difference in DBS and plasma concentrations could very well be explained by compound-specific plasma protein binding and haematocrit using an adapted version of a formula previously proposed by Li and Tse. 9 The mean difference between measured and theoretical plasma concentrations using the measured haematocrit for nevirapine and efavirenz was 0.29 and 0.08 mg/L, respectively. This difference may have resulted in different clinical decisions in 10% of the efavirenz cases (Table 2) . However, in clinical practice this difference may be less pronounced since the discrepancies between differently categorized concentrations were small. For example, in two of the four cases all efavirenz concentrations were around 1.0 mg/L (1.01, 0.68 and 0.89, 1.00 mg/L for the measured plasma concentrations and theoretical plasma concentration using patient-specific haematocrit, respectively). No dose adjustment is recommended with a measured plasma concentration of 1.01 mg/L according to categorization. However, since this concentration is at the boundary of acceptance, in clinical practice a dose increase may be advised if a specific patient is failing virologically despite adherence. Thus, despite different categorization of the measured and theoretical plasma concentrations, clinical practice in these patients may be similar.
The mean difference between measured plasma concentrations and theoretical plasma concentrations using mean haematocrit for males (0.43 and 0.17 mg/L for nevirapine and efavirenz, respectively) was significantly higher than the mean difference between measured plasma concentrations and theoretical plasma concentrations using measured haematocrit (P ¼ 0.007 and 0.009 for nevirapine and efavirenz, respectively). However, no difference in efavirenz categorization was found, showing the two methods performed similarly when used for TDM purposes.
A limitation of this study is that we did not investigate patient-specific plasma protein binding and binding to red blood cells. On average, efavirenz is highly bound (99.5%) to plasma proteins, mainly albumin, whereas binding of nevirapine to plasma proteins is 60%. 13 Inter-patient variability in albumin levels might result in inter-patient variability in plasma protein binding, thereby causing some bias. However, we investigated albumin levels in all patients and found albumin levels within the normal range (35-50 g/L) except for one patient (33 g/L). Thus, the variability in plasma protein binding of efavirenz and nevirapine in this population is thought to be minimal, thereby limiting potential bias. Additionally, the binding of nevirapine and efavirenz to red blood cells is thought to be limited. Binding of nevirapine and efavirenz to red blood cells may cause bias in the calculation of plasma concentrations from DBS concentrations. However, we showed that plasma concentrations could be adequately predicted by plasma protein binding and haematocrit. This indicates that preferential uptake in red blood cells was minimal, which can be expected from the relatively high plasma protein binding of both drugs. Another limitation is that our study population mainly included male patients. For calculation of the plasma concentrations we therefore used the mean haematocrit of males. Since the mean haematocrit of women and children is different, confirmation of our results in these populations is needed.
To conclude, the results of this study enable DBS sampling of nevirapine and efavirenz for TDM purposes. The theoretical plasma concentration can be calculated from DBS concentrations with the formula: [DBS [ Theoretical plasma levels using patient-specific haematocrit (mean male haematocrit) Nevirapine and efavirenz in dried blood spots due to ethical considerations, and in resource-limited settings, where equipment for plasma sampling is often not available. Evaluation of other antiretroviral drugs is currently ongoing.
